Asia Fresh News

Asia Fresh Stories

Archive for March 1st, 2017

RTLS and Asset Tracking Technologies to Catalyze Next-Generation Fleet Telematics, Retail, and Manufacturing Solutions

leave a comment »

LONDON/PRNewswire/ — The potential surrounding next-generation RTLS and asset tracking technologies will move from proof of concept to full scale deployments in 2017, laying the foundation for a break out year in 2018, forecasts ABI Research.

ABI Research is beginning to see BLE beacon and other next-generation RTLS and asset tracking technology deployments in the transport and logistics, healthcare, retail, manufacturing, and commercial buildings verticals. The low-cost, high-accuracy combination is creating new opportunities in applications like pallet tracking, condition monitoring, last mile delivery, inventory, and tools/asset tracking. Beacons, which are also well-suited for consumer asset tracking, will continue to accelerate significantly in 2017 and 2018, as large beacon networks help catalyze the critical end user population.

With a growing number of startups with strong IPs infiltrating the market landscape, industry incumbents need to understand who they should collaborate with and what new technology initiatives will start to take form. HID Global recently acquired high-accuracy startup Bluvision, and Cisco invested in MIST Systems. ABI Research expects to see more investments, partnerships, and acquisitions over the next two years.

While active RFiD is starting to look outdated and expensive in comparison to new technologies, passive RFiD remains the overbearing entity in the RTLS and asset tracking market, particularly with retail migrating to in-store item level tracking. This was a big trend at NRF this year, with Zebra launching its new SmartSense technology, while Intel demoed its new Retail Sensor Platform. Though the industry is still three to four years away from passive BLE, startups are working on the problem. In the short-to-medium term, ultra wideband technology could be become an interesting alternative, given its high accuracy.

These findings are from ABI Research’s BLE Beacon Technologies, Applications, and Revenues (https://www.abiresearch.com/market-research/product/1022883-ble-beacon-technologies-applications-and-r/) report.

About ABI Research

ABI Research stands at the forefront of technology market research, providing business leaders with comprehensive research and consulting services to help them implement informed, transformative technology decisions. Founded more than 25 years ago, the company’s global team of senior and long-tenured analysts delivers deep market data forecasts, analyses, and teardown services. ABI Research is an industry pioneer, proactively uncovering ground-breaking business cycles and publishing research 18 to 36 months in advance of other organizations. For more information, visit www.abiresearch.com.

Contact Info: Mackenzie Gavel               

Tel: +44.203.326.0142

pr@abiresearch.com

Logo – http://mma.prnewswire.com/media/276887/abi_research_logo.jpg

Source: ABI Research

Written by asiafreshnews

March 1, 2017 at 5:23 pm

Posted in Uncategorized

Frost & Sullivan Lauds SnooZeal’s Unique Electrical Stimulation Therapy for Sleep Apnea in the European Market

leave a comment »

-SnooZeal offers superior value to patients by addressing both sleep apnea and snoring

LONDON/PRNewswire/ — Based on its recent analysis of the sleep apnea therapy market, Frost & Sullivan recognizes SnooZeal, Inc. with the 2017 European New Product Innovation Award. SnooZeal is a highly innovative product that intelligently addresses the root causes of sleep apnea by training the tongue muscles through the clinically proven continuous transmucosal electrical stimulation therapy. Because of its over-the-counter (OTC) status, SnooZeal is one of the most accessible anti-snoring products available in the market today. This ease of access has enabled the company to build a clear competitive advantage in terms of early market access.

SnooZeal Receives 2017 European Sleep Apnea Therapies New Product Innovation Award
SnooZeal Receives 2017 European Sleep Apnea Therapies New Product Innovation Award

Unlike competitive anti-snoring therapies widely prescribed as viable treatment options for sleep apnea patients, SnooZeal’s product is based on the simple principle of electrically stimulating the tongue muscles in a non-invasive manner to exercise the over-relaxed muscles. SnooZeal is the only product in the European market used as a therapy during waking hours, enhancing patient convenience and adherence. To be cured of various stages of sleep apnea, the user needs to wear the mouthpiece for at least 20 minutes twice a day for a minimum of 6 weeks.

“The device is designed to accommodate the treatment needs of patients suffering from various degrees of sleep-disordered breathing by optimizing treatment parameters, which are clinically demonstrated to deliver best results and autonomy to patients,” said Frost & Sullivan Industry Analyst Arjunvasan Ambigapathy. “SnooZeal anti-snoring therapy helps patients consciously correct their symptoms, which is clinically demonstrated to be more effective than therapies that are administered when the patient is unconscious. SnooZeal is the only therapeutic option aimed at reversing the cause of this condition, a value that is not seen in most widely-prescribed products in the market today.”

One of SnooZeal’s most innovative features is its simple design comprising three components:

  • a wearable mouthpiece in the form of a glove that fits onto the tongue
  • a rechargeable control unit attached to the mouthpiece through a mini-USB connection
  • a remote control unit and a smartphone app to manage various treatment parameters that are ideal for patients

When designing the mouthpiece, SnooZeal’s team worked with various dentists and maxillofacial surgeons to ensure the product is flexible enough to cover and fit various tongue sizes, without restricting its potential for OTC sales across specific geographies. The product’s ease of use; enhanced mobile connectivity; and better collaboration with care providers before, during, and after the therapy have made SnooZeal a truly user-friendly, innovative medical device.

Within a year of its inception, SnooZeal received commercial approval from European healthcare authorities to offer its product OTC as a clinically safe and effective alternative to sleep apnea therapy. The product is awaiting approval from the Food and Drug Administration (FDA) and will soon be available in the United States, which had subsequently garnered the attention of leading investors.

“Being CE-approved for sale in the European market, SnooZeal aims to present its products across both retail and online channels in the United Kingdom, Germany, Switzerland, France, and other major European economies in the near future,” noted Arjunvasan Ambigapathy. “With plans to expand its market across emerging economies such as Russia, Mexico, India, China, Canada, and Brazil, SnooZeal’s net market value could be higher than most medical device companies in this emerging industry sector and most other companies operating within the European market today.”

For successfully meeting the core customer requirements of quality, functionality, clinical effectiveness, and reliability, SnooZeal’s sleep apnea product richly deserves Frost & Sullivan’s honour.

Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leveraging leading-edge technologies. The award recognizes the product’s value-added features/benefits and the increased return on investment (ROI) it offers customers, which in turn raise customer acquisition and overall market penetration potential.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About SnooZeal, Inc.

SnooZeal’s antisnoring and sleep apnea device scored a CE mark, making it the first commercially available over-the-counter device that targets the underlying cause of snoring.

The SnooZeal device addresses the excessive relaxation and loss of tongue muscle tone during sleep. The device is worn for 20 to 25 minutes twice a day over six weeks. It delivers electric pulses to the back of the tongue to increase muscle tone with the goal of reversing the over-relaxation of the tongue during sleep. The patient uses a smartphone app to control the treatment.
The daytime treatment differentiates SnooZeal from currently available treatments that are used at night.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, collaborates with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that could make or break today’s market participants. For more than 50 years, Frost & Sullivan has been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the Discussion.

Contact:

Chiara Carella
P: +44 (0) 207.343.8314
F: 210.348.1003
E: chiara.carella@frost.com

Photo – http://photos.prnasia.com/prnh/20170222/8521701057

Source: Frost & Sullivan
Related Links:

Written by asiafreshnews

March 1, 2017 at 5:01 pm

Posted in Uncategorized

Thammasat University to Install Largest Solar Rooftops In Asia

leave a comment »

BANGKOK /PRNewswire/ — Thammasat University (TU), Thailand’s secondoldest university, has launched an initiative to install solar panels on its rooftops for intra-campus electricity generating with the goal of reaching overall production of 15 megawatts by the end of 2017, the biggest among all universities in Asia and the fourth-largest in the world. Professor Dr. Somkit Lertpaithoon, Thammasat University rector, said the move was part of TU’s “Sustainable University” project. The solar rooftops are set to be installed at the university’s Rangsit Campus in two phases. The first phase will generate a total of six megawatts of power and the second phase will bring the total to nine megawatts by the end of 2017.

Thammasat University's solar rooftops
Thammasat University’s solar rooftops

Currently, the top three universities in the world with the highest capacity of electricity generated from solar cells are Colby College at 30 megawatts, Arizona State University at 24 megawatts and the University of California at 16 megawatts. All three are located in the US.

If the initiative is completed in 2017, the rector said that TU will become the number one university in Asia in terms of rooftop power generating, replacing Nanyang Technological Univeristy in Singapore, which generates five megawatts of electricity from its current rooftop project, the world’s fourth-most, after the three US-based universities.

TU deputy rector Parinya Thewanarumitkul said that fossil consumption is the major factor behind global warming and climate change. Thailand generates nearly 70% of its electricity from fossil fuel. The initiative will help support TU to generate around 30-40% of its own electricity.

Photo – http://photos.prnasia.com/prnh/20170228/8521701247

Source: Thammasat University

Written by asiafreshnews

March 1, 2017 at 4:58 pm

Posted in Uncategorized

OKLink Makes Cross-border Transfers to Singapore Free of Charge

leave a comment »

Offering the cheapest, fastest, and most transparent global remittance services

SINGAPORE /PRNewswire/ — OKLink, the next generation global settlement platform, today announced the first completely free corridor for remittances. Transfers of up to US$100,000 per month in to Singapore will be free of charge for all of 2017.

Up to now, the cheapest way to make cross-border payments to Singapore has been through OKLink at 0.1% but some companies are charging up to US$5 per transaction.

Jack C. Liu, Chief Strategy Officer at OKLink, said, “As the world’s largest global settlement network powered by blockchain, we can conduct cross-border payments faster and at a cheaper rate as more partners join the network. We believe that our initiative will make a revolutionary impact on the global economy, especially for markets with a high degree of overseas workers. There is no better alternative for Singapore today.”

OKLink’s global blockchain network is radically transforming the way money is transferred by both individuals and institutions, making it cheaper, faster and easier. Launched in August 2016, it currently offers payouts to 40 countries across Asia, Europe, and the Americas, and already has more than 100 partners on its network. As of December 2016, OKLink had completed over 10,000 transactions via its settlement network.

Transfers to Singapore can be made after registering an account on www.oklink.com, and can be paid out to the receiving account as quickly as within one business day.

About OKLink

Launched in August 2016, OKLink is a next generation settlement platform provider that gives every remittance and payment company the same cost advantage, global reach, and speed that took Western Union many decades to build. The company leverages the trust of the blockchain to connect and enable transactions between transfer and delivery companies worldwide using blockchain anchored digital assets and multi-signature technology. OKLink is growing rapidly with a payout network that is currently available in 40 countries across Asia, Europe and the Americas.

For more information, please visit oklink.com or follow the company on Twitter @OKLink.

Source: OKLink
Related Links:

Written by asiafreshnews

March 1, 2017 at 4:52 pm

Posted in Uncategorized

Enea and Lanner Demonstrate Multi-architecture Proof-of-Concept vCPE Solution at Mobile World Congress

leave a comment »

-Life at the Edge Made Easy With NFV Platform for Virtualized Customer Premise Equipment (vCPE)

STOCKHOLM/PRNewswire/ —

Enea® (NASDAQ OMX Nordic:ENEA) together with Lanner Electronics Inc. (TAIEX 6245) today announced a Proof-of-Concept (PoC) of a commercial Network Function Virtualization (NFV) solution built on OPNFV running on both x86 and ARM based COTS hardware. Using Commercial Off-The-Shelf (COTS) virtual Customer Premise Equipment (vCPE) brings a promise of lower cost and lower power consumption, and equips customers with better architectural choice for their specific use case.

vCPE is clearly among the hottest topics in the NFV discussion today and together with Lanner, Enea will demonstrate a unique ability to mix hardware platform architectures in Enea’s stand 6H21 in Hall 6 at the Mobile World Congress in Barcelona, February 27 to March 2, 2017.

The NFV edge Proof-of-Concept

The PoC shows how NFV will help to push functionality and data streams to the edge where it can run on cheaper hardware and not congest the network.

Enea will run its network virtualization software platform on a central office server that sets up and initiates a video call between two tablets; one connected to an x86 based Lanner device, and one connected to an ARM based device. The demo highlights how data can stream between two efficient vCPE devices without putting a load on nodes in the network.

“Our OPNFV based software platform is flexible enough to seamlessly mix different vCPE architectures, and delivers the characteristics necessary for leveraging the benefits of NFV in the edge use case”, said Karl Mörner, SVP Product Management at Enea. “With the Enea NFV, customers save time-to-market and cost, while opening up for new revenue streams and guaranteeing better customer satisfaction.”

“As the world leader in network appliances, we engineer and manufacture vCPE devices based on x86 and ARM platforms,” said Jeans Tseng, Vice President of Telecommunication Applications at Lanner. “With validation through Enea’s NFV software, Lanner and Enea can deliver vCPE solutions optimized for next-gen hybrid NFV architecture and help accelerate time-to-market for service providers and telecom equipment manufacturers”.

Further reading

Enea NFV Lab: http://www.enea.com/solutions/pharos-lab/

Enea NFV Lab services: http://services.enea.com/services/packaged-services/enea-nfv-lab

Enea at the Mobile World Congress: http://www.enea.com/about-us/Events/Trade-shows/Mobile-World-Congress-2017/

Lanner network appliances: http://www.lannerinc.com/products/network-appliances/x86-rackmount-network-appliances/nca-4010

Contact:

Fredrik Medin,
SVP Marketing and Communications
Phone: +46-709-71-40-11
E-mail: fredrik.medin@enea.com

About Lanner

Lanner Electronics Inc (TAIEX 6245) is a world leading provider of design, engineering and manufacturing services for advanced and customizable SDN and NFV network computing appliances for system integrators, service providers and application developers. Lanner possesses a wide range of network appliances including desktop vCPE devices designed for SD-WAN and SD-Security, as well as NEBS-compliant, NFVi-ready platforms with multiple processors, network I/O blades, and high availability features. www.lannerinc.com

About Enea

Enea is a global supplier of network software platforms and world class services, with a vision of helping customers develop amazing functions in a connected society. We are committed to working together with customers and leading hardware vendors as a key contributor in the open source community, developing and hardening optimal software solutions. Every day, more than three billion people around the globe rely on our technologies in a wide range of applications in multiple verticals – from Telecom and Automotive, to Medical and Avionics. We have offices in Europe, North America and Asia, and are listed on NASDAQ OMX Nordic Exchange Stockholm AB. Discover more at www.enea.com and start a conversation at info@enea.com.

Enea®, Enea OSE®, Netbricks®, Polyhedra®, Zealcore®, Enea® Element, Enea® Optima, Enea® LINX, Enea® Accelerator,  Enea® dSPEED Platform and COSNOS® are registered trademarks of Enea AB and its subsidiaries. Enea OSE®ck, Enea OSE® Epsilon, Enea® Optima Log Analyzer, Enea® Black Box Recorder, Polyhedra® Lite, Enea® System Manager, Enea® ElementCenter NMS, Enea® On-device Management and Embedded for LeadersTM are unregistered trademarks of Enea AB or its subsidiaries. Any other company, product or service names mentioned above are the registered or unregistered trademarks of their respective owner. All rights reserved. © Enea AB 2017. 

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/enea-ab/r/enea-and-lanner-demonstrate-multi-architecture-proof-of-concept-vcpe-solution-at-mobile-world-congre,c2195332

The following files are available for download:

 

Source: Enea AB

Written by asiafreshnews

March 1, 2017 at 4:44 pm

Posted in Uncategorized

NeuroVive Appoints Recognized Scientific Advisors and Enters Research Agreements in NASH and Hepatocellular Carcinoma

leave a comment »

LUND, Sweden /PRNewswire/ — NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced two new research agreements and the appointment of Professor Philippe Gallay, PhD, and Professor Massimo Pinzani, MD, PhD, FRCP, as scientific advisors. The aim of the agreements is to further explore NeuroVive’s new drug compounds in development for the treatment of NASH and hepatocellular carcinoma (HCC).

In the new collaboration with Philippe Gallay, the research teams will explore the mechanisms of action of the potent anti-cancer effects of NeuroVive’s novel sanglifehrin-based compounds. These studies will be an important part in NeuroVive’s HCC lead candidate selection process.

“I am enthusiastic about continuing the fruitful collaboration with the NeuroVive research team. NeuroVive’s potent drug compounds have unique and promising features that I am really excited in continuing to explore” said Prof. Philippe Gallay.

In the collaboration with Massimo Pinzani, the research groups at Engitix Ltd and NeuroVive will assess the anti-fibrotic properties of NV556 by using Engitix’ human liver 3D models. The models offer an important opportunity to evaluate and validate effects in appropriate pathophysiological conditions.

“Fibrosis is a critical part of the progression of several liver diseases including NASH, and I look forward to further study the anti-fibrotic effects of NeuroVive’s new drug compounds and how they may contribute to fill the unmet medical need in this area”, said Prof. Massimo Pinzani.

“I am very pleased that Philippe Gallay and Massimo Pinzani have joined our efforts in advancing the research and development of our NASH and HCC treatment opportunities” said Magnus Hansson, Chief Medical Officer at NeuroVive. “Their scientific guidance as experts in the field of liver disease mechanisms and clinical management will be most valuable in the continued development of our project pipeline, as well as in the ultimate positioning of our candidate drugs in the future treatment landscape.”

Philippe Gallay is Professor of Immunology at the Department of Immunology and Microbiology at the well esteemed Scripps Research Institute in California, US. Phillipe Gallay and NeuroVive has previously worked together with the company’s cyclophilin inhibitor platform, a research effort that focused on the most potent cyclophilin inhibitor so far developed, NV556.

Massimo Pinzani is Professor of Medicine, clinical hepatologist and Director of the University College London (UCL) Institute for Liver and Digestive Health, UK. He also holds the prestigious chair of the Sheila Sherlock Liver Centre at the Royal Free Hospital in London and he is the Chairman of Engitix Ltd.

About Engitix Ltd

Engitix Ltd is a spin-out from the UCL Institute for Liver and Digestive Health, based at the Royal Free Hospital, London. Engitix is using its proprietary human organ decellularization technology to develop tissue engineered products for application in regenerative medicine and drug target research. Engitix’ core expertise is human whole-liver and tissue-specific and disease specific ECM (extra cellular matrix) scaffolds for treatment and research of liver disease.

About hepatocellular carcinoma (HCC) and NeuroVive’s project NVP024

Liver cancer includes two major types: hepatocellular carcinoma (HCC) and intrahepatic bile duct cancer. HCC is the sixth most-common type of cancer and the third most-common cause of death worldwide. HCC patients have a high medical need for new and effective treatment alternatives.

NeuroVive’s NVP024 project is focused on the company’s new generation of sanglifehrin-based compounds which have shown potent inhibitory effects on HCC cells and anti-cancer activity in an experimental model of HCC.

About NASH and NeuroVive’s projects NV556 and NVP022

Fatty liver, fibrosis and inflammation are hallmarks of NASH, a condition that can lead to cirrhosis of the liver or liver cancer. There is a strong link between NASH and other metabolic disorders, such as diabetes and obesity. About 3-5% of all Americans (about 15 million people) suffer from NASH and there are currently no registered treatments.

NV556 is a potent cyclophilin inhibitor in NeuroVive’s Sangamide class of compounds. NV556 has shown an inhibitory effect on fibrosis development in an experimental model of NASH. NVP022 is a novel class of compounds that has a completely different mode of action than NV556 that may complement NV556 in the treatment of NASH. NVP022 is targeting mitochondrial metabolic pathways in NASH.

About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company’s strategy is to take drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production.

NeuroVive has a project in early clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH.

NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

For investor relations and media questions, please contact:

Cecilia Hofvander
NeuroVive
Tel: +46 (0)46-275-62-21 or ir@neurovive.com

Charles Athle Nelson
NeuroVive US representative
Tel +1 212-961-6277 or ir.usa@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46-275-62-20 (switchboard)
www.neurovive.com

This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 10:30 a.m. CET on February 22, 2017.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/neurovive-pharmaceutical/r/neurovive-appoints-recognized-scientific-advisors-and-enters-research-agreements-in-nash-and-hepatoc,c2195673

The following files are available for download:

http://mb.cision.com/Main/6574/2195673/633013.pdf

NeuroVive appoints recognized scientific advisors and enters research agreements in NASH and hepatocellular carcinoma

Source: NeuroVive Pharmaceutical

Written by asiafreshnews

March 1, 2017 at 4:09 pm

Posted in Uncategorized

Kuala Lumpur is the Most Affordable City for Students, according to QS Survey

leave a comment »

-Lower Cost of Living and Good Student Experience Contribute to KL’s Improved Rankings as Best Student Cities

JAKARTA, Indonesia /PRNewswire/ — Malaysia is ranked the 12th preferred education destination (UNESCO 2014) and its capital city, Kuala Lumpur is ranked the Most Affordable City for Students in a QS survey which analysed 125 cities and responses from 18,000 international students worldwide. Kuala Lumpur also climbed 8 positions to rank 41 in the QS Best Student Cities Survey 2017.

“With quality programmes, reasonable tuition fee, lower cost of living, coupled with geographical and cultural proximity, Malaysia is the ideal higher education destination for Indonesians, be it for a postgraduate, undergraduate or foundation programme and for skills, vocational or language courses,” said Mohd Yazid Abd Hamid, Chief Executive Officer of Education Malaysia Global Services (EMGS).

“There are over 6,000 courses and almost 300 higher education institutions (HEIs) to choose from. For an international certification, students can choose to enroll in the six British, three Australian and one Chinese university which have branch campuses in Malaysia and enjoy at least 30% savings from lower tuition fee and lower cost of living. 3 of these universities rank in the top 100 global universities ranking. Colleges in Malaysia offer twinning programmes with partner universities globally where students will graduate with a certificate from the foreign institution. Leading universities in Malaysia offer joint degree programmes with reputable foreign partners to provide option for students to study in two campuses in two countries and graduate with dual certification from both institutions.

“We have established business, accounting and finance programmes. The International Islamic University Malaysia leads in Islamic Banking and Finance and is the largest single source of global publications in the Islamic banking field. Our Engineering programmes are Washington Accord accredited – graduates can practice in the UK, USA, Australia, Japan, Canada and many other countries. We have a wide range of arts and creative programmes covering multimedia, graphic design, broadcasting and fashion design. We also attract many international students in our culinary schools,” Mohd Yazid explained to students at the World Education Expo Festival in Jakarta, held over the weekend.

A 3-year degree programme costs a minimal USD9,000. An Australian, American or British Degree Transfer Programme will cost USD7,000-12,000 for two years of study in Malaysia. For USD500 a month on accommodation, food and other expenses, students can live comfortably.

Indonesian students can apply to study in Malaysia with the Ijazah SMU3, SMA and SMK. Students need to apply directly to the institution and upon receiving a Letter of Offer, the student may apply online for a Student Visa with EMGS. The student will receive a Visa Approval Letter (VAL) within 14 working days to travel and obtain entry into Malaysia. Students are advised to apply for the VAL six weeks before the commencement date of study.

For detailed information, visit EMGS website www.educationmalaysia.gov.my. Education Malaysia Indonesia can be reached at 021-5222270 or email pemasaranpendidikan@yahoo.com.

Source: Education Global Malaysia Services

Written by asiafreshnews

March 1, 2017 at 12:15 pm

Posted in Uncategorized

Experts Call On Countries to Accelerate Regional Collaboration to Tackle Dengue Crisis

leave a comment »

— Infectious diseases experts and public health authorities unite at Asia Dengue Summit to address rising dengue burden
— Asia saw one of the worst outbreaks in 2016 with several countries — Philippines, Thailand, Malaysia, Sri Lanka — reporting a record high

MANILA, Philippines /PRNewswire/ — Over the past year, many countries in Asia have witnessed an alarming rise in the number of dengue cases that account for more than 70% of the global dengue cases[1].  This translates to an overwhelming 273 million dengue infections per year out of the projected 390 million[2] cases both reported and unreported worldwide.

In light of the rapidly increasing burden, leading infectious disease experts from around the world together with government officials, policymakers and public health authorities will convene at the Asia Dengue Summit to identify strategies that can effectively support Asian countries in their fight against dengue.

The two-day Summit, which will start in Manila on March 1, is organized by the Asian Dengue Vaccination Advocacy (ADVA), a scientific working group, in partnership with the South East Asian Ministers of Education Tropical Medicine and Public Health Network (SEAMEO TROPMED).

Experts at the summit will discuss the concrete steps needed to address the worrying rise in dengue cases as well as new developments in the area of prevention and control. The outcome at the Summit will help in formulating a roadmap for countries in Asia to implement collaborative and cost-effective strategies for dengue prevention and vector control measures.

Speaking at the sidelines of the Summit, Prof Usa Thisyakorn, Professor of Pediatrics at Chulalongkorn University and Chairman of ADVA, said, “The success of the inaugural Asia Dengue Summit (ADS) last year shows that countries acknowledge the need to join forces to tackle the situation in Asia. A collaborative approach which encourages the sharing of research findings, epidemiological trends, disease surveillance methods and vaccine implementation strategies will allow countries to harmonise their existing dengue prevention and control efforts. In the war against dengue countries should fight together, not alone.”

“At the Summit this year, we aim to build on the on-going efforts of countries, strengthen the implementation of vector control, as well as prevention measures such as the use of the dengue vaccine that can ultimately benefit the local population,” Prof Thisyakorn further added.

ONE OF THE MOST PRESSING HEALTHCARE ISSUES OF OUR TIMES

Dengue continues to be one of the most devastating and prevalent mosquito-borne viral diseases on the planet. In the last 50 years, this deadly disease has spread from a handful of countries to over 128 countries and the incidence has increased 30-fold in this time.

The severe burden comes at a great cost  financially and in the number of lives lost. Worldwide, dengue is estimated to cost about $9 billion annually, and in Southeast Asia, the economic toll for dengue was estimated at almost $1 billion on average per year from 2001 to 2010[3].

External factors such as unprecedented urbanization and globalisation have resulted in large mosquito populations living in association with crowded human populations, leading in increased transmission and geographic spread of the viruses, making it difficult to combat dengue outbreaks. In addition, environmental factors including inadequate housing, water, sewage and waste management systems have contributed to an increase in the Aedes Aegypti mosquito populations.

This calls for urgent intervention and collaboration between countries towards detection, management and control to stem the spread of dengue across the region.

Prof Duane Gubler, Emeritus Professor, Duke-NUS Medical School, Singapore, and Chair of Global Dengue and Aedes-Transmitted Diseases Consortium, said, “The Summit represents a major turning point in Asia’s fight against dengue as more countries unite to strengthen and sustain cross-border efforts. Dengue is a disease that must be controlled at the regional level.  Countries should continue this momentum at the grassroots via public education and at the national level through vector control and vaccination.”

“The recently released WHO position paper on dengue vaccine supports the use of vaccination to help prevent dengue as part of a comprehensive dengue control strategy in each endemic country, especially in areas where there is a high burden of disease,” Prof Gubler further said.

The dengue vaccine could serve as a new line of defense to complement vector control and other prevention efforts by governments, families and individuals, having a greater impact on the disease burden, keeping dengue under control. WHO has laid out the goal of the global strategy to reduce the dengue mortality by 50% and morbidity by 25% by 2020 in endemic countries[4].

BUILDING A KNOWLEDGE ECOSYSTEM

Philippines was the first country in Asia to approve the use of the dengue vaccine in December 2015. Since then four other Asian countries, Indonesia, Singapore, Thailand and Cambodia, have approved the vaccine for use for the age group of 9-45 year olds broadly.

Advocating an information-sharing approach to effectively control the disease from reaching epidemic proportions, Prof Lulu Bravo, Professor of Pediatric Infectious and Tropical Diseases, University of the Philippines Manila, said, “Philippines has been a front-runner in dengue prevention and became the first country in the world to launch a public immunisation programme. At the Summit, we will share our first-hand experience over the last one year, which shows that vaccine introduction should be part of a comprehensive dengue control strategy, including well-executed and sustained vector control, evidence-based best practices for clinical care and strong dengue surveillance.”

The Summit will serve as a platform for the sharing of best practices and knowledge exchange among countries. New models for ongoing dengue efforts such as the recent Wolbachia study conducted in Singapore, which showed that male Wolbachia-carrying Aedes aegypti mosquitoes could help in suppressing the population of urban Aedes aegypti mosquitoes, and other initiatives including community engagement and outreach programmes.

About Asian Dengue Vaccine Advocacy (ADVA):

The Asian Dengue Vaccine Advocacy (ADVA) Group is a scientific working group dedicated to dengue vaccine advocacy in Asia, with the aim of disseminating information and making recommendations on dengue vaccine introduction strategies in Asia.

ADVA was set up in 2011 to identify opportunities and make practical recommendations for improving surveillance and laboratory capacity for dengue disease confirmation. For more information, you may visit ADVA’s website here.

Media Contact for ADVA:

Shruti Bose
+65-6825-8018
SBose@webershandwick.com

Clarinda Ng
+65-6825-8042
CNg2@webershandwick.com

Sources:

Source: Asian Dengue Vaccination Advocacy (ADVA)

Written by asiafreshnews

March 1, 2017 at 12:09 pm

Posted in Uncategorized

MediaTek Unveils Helio X30 to Power Premium Mobile Experiences

leave a comment »

-Full-featured 10-core chipset delivers power efficiency, sustained high performance, blazing fast connectivity and a powerhouse of multimedia technology to smartphones

BARCELONA, Spain /PRNewswire/ — Today at Mobile World Congress, MediaTek Inc. announced the commercial availability of its MediaTek Helio X30 system-on-chip (SoC), the most powerful addition to the Helio family for today’s high-end smartphones. MediaTek Helio X30 is entering mass production and gaining accolades with design wins. Smartphones powered by this flagship chipset will be available in Q2 2017.

The MediaTek Helio X30 brings together MediaTek’s 10-core, Tri-Cluster architecture on its first 10nm chipset—the most advanced fabrication technology in the market—to deliver more than 50 percent power savings and a 35 percent increase in performance from MediaTek’s previous generation chipset.

“We’re asking our smartphones to do more than ever. MediaTek designs smart chipsets that deliver exactly what the device and user need, on demand and when they need it,” said Jeffrey Ju, Executive Vice President and Co-COO of MediaTek. “MediaTek’s Helio X30 fuses together state-of-the-art processing architecture, fabrication and connectivity to provide an unparalleled mobile experience. This powerhouse chipset is another example of our vision to bring premium mobile experiences to life.”

MediaTek introduced its first Helio chipset at Mobile World Congress in 2015. The MediaTek Helio X30 represents improvements in all aspects of the MediaTek Helio platform. The chip’s full-featured design and architecture includes:

  • 10nm, 10-Core, Tri-Cluster architecture built for extreme performance: two ARM Cortex-A73 at 2.5 GHz, four ARM Cortex-A53 at 2.2 GHz and four ARM Cortex-A35 at 1.9 GHz.
  • LTE WorldMode Cat.10 modem fulfills smartphone users’ need for speed with seamless connectivity, supporting for three downlink Carrier Aggregation (3CA) and two uplink Carrier Aggregation (2CA) for high volume content streaming.
  • Imagination PowerVR Series7XT Plus clocked at 800MHz, is a tailored GPU for MediaTek Helio X30. It offers power savings up to 60 percent while increasing performance by up to 2.4 times compared to the GPU in MediaTek Helio X20.
  • Built in multimedia features deliver next-generation experiences. And it’s the industry’s first mobile SoC to bring a power-efficient, hardware based 4K2K 10-bit HDR10 video decoding to smartphones. The camera zoom feature offers 2x optical zoom in a super slim form factor.

Sustained processing power
Incorporating MediaTek’s newest version of CorePilot 4.0 technology and Tri-Cluster architecture, MediaTek Helio X30 delivers a variety of resource configurations and intelligently directs optimal power where and when its needed across multiple processing cores.

CorePilot 4.0 incorporates an intelligent task scheduling system, thermal management and user experience monitoring systems. This combination can predict an individual’s power usage scenario on the device and prioritize which application is most critical at that point in time to control power consumption. This translates to longer device battery life and stronger performance that makes the most of the Helio X30’s 10-core architecture.

A multimedia powerhouse
MediaTek Helio X30 is a multimedia powerhouse that supports major commercial Virtual Reality SDKs. MediaTek Helio X30 also incorporates two 14-bit image signal processors to support 16 MP + 16MP dual cameras, delivering advanced functionality such as wide + zoom combination lenses for real-time depth of field effects, fast auto exposure and real-time de-noise in low-light condition features.

Smartphones powered by MediaTek Helio X30 enjoy crisp images at high zoom ratios thanks to proprietary ClearZoom and Temporal Noise Reduction (TNR) technologies. ClearZoom ensures signal fidelity while TNR reduces video temporal noise and preserves image details.

MediaTek Helio X30 also has a new a built-in Vision Processing Unit (VPU) paired with MediaTek’s Imagiq 2.0 image signal processor technology. The combination provides a dedicated processing platform for numerous camera features, which frees up the CPU and GPU saving power. More importantly, it provides programmability and flexibility for phone makers to customize camera features.

For more details on the MediaTek Helio X30, please visit: https://www.mediatek.com/products/smartphones/mediatek-helio-x30

About MediaTek

MediaTek Incorporated (TWSE: 2454) is a global fabless semiconductor company that enables 1.5 billion connected devices a year. We are a market leader in developing innovative systems-on-chip (SoC) for mobile device, home entertainment, connectivity and IoT products. Our dedication to innovation has positioned us as a driving market force in several key technology areas, including highly power-efficient mobile technologies and advanced multimedia solutions across a broad range of products such as smartphones, tablets, digital televisions, OTT boxes, wearables and automotive solutions. MediaTek empowers and inspires people to expand their horizons and more easily achieve their goals through smart technology. We call this idea Everyday Genius and it drives everything we do. Visit www.mediatek.com for more information.

MediaTek Press Office:
PR@mediatek.com

Kevin Keating, MediaTek
+1- 206-321-7295
10188 Telesis Ct #500, San Diego, CA 92121, USA

Joey Lee, MediaTek
+886 3-567-0766 # 31602
No. 1, Dusing 1st Rd., Hsinchu Science Park, Hsinchu City 30078, Taiwan

 

Source: MediaTek Inc.

Related stocks: OTC-PINK:MDTKF Taiwan:2454

Related Links:

Written by asiafreshnews

March 1, 2017 at 10:59 am

Posted in Uncategorized

MediaTek Announces CorePilot 4.0 Technology to Deliver Ultimate Processing Power and Power Efficiency to Smartphones

leave a comment »

-Intelligent technology automatically manages smartphone tasks to give users the best experience and longest battery life

BARCELONA /PRNewswire/ — MediaTek today announced CorePilot 4.0, an advanced technology that intelligently manages smartphone tasks to deliver the perfect balance of processing power and battery life. CorePilot 4.0 is available on MediaTek’s newest SoC, the MediaTek Helio X30. CorePilot 4.0 can deliver up to 25 percent more power savings over the previous version which means end users can do more with their smartphone, for longer.

CorePilot 4.0 uses intelligent task scheduling system along with thermal management and user experience monitoring technology to prioritize smartphone tasks and predict power usage. As a result, CorePilot directs devices to run in the most power efficient mode based on what the user needs.

“Just like your heart automatically reacts to numerous tasks your body is doing, CorePilot 4.0 automatically directs power where and when it’s needed to maintain efficiency,” said Jeffrey Ju, Executive Vice President and Co-COO of MediaTek. “Consumers today demand extreme performance from their smartphones, on top of a long battery life. CorePilot 4.0 perfectly balances power and efficiency, and adapts to users’ computing patterns to manage power consumption.”

CorePilot 4.0 is built on MediaTek’s groundbreaking Tri-Cluster processing architecture. The three clusters offer minimum, medium and maximum processor levels to better balance the vast needs and requirements of smartphone applications and tasks.

Many smartphone processors offer only two types of cores. A high performance set of cores which requires a lot of battery power and low energy, low performance cores. MediaTek’s Tri-Cluster configuration provides extra flexibility needed to achieve an optimal balance of power and efficiency.

CorePilot 4.0 includes a centralized intelligent task scheduling system that optimizes energy efficiency. Other new CorePilot 4.0 features include UX Monitoring and System Power Allocator (SPA), a sophisticated thermal management. The System Power Allocator predicts an individual’s power usage scenario. It prioritizes which application is most critical for the user in the moment and controls power consumption. The UX Monitoring in CorePilot 4.0 analyzes system feedback on the current display framerate, activities happening in the foreground and actions that require immediate performance.

Working together, CorePilot 4.0 chooses the right cluster or clusters at a select frequency that yields an optimal voltage for the current load. This provides a consistent and sustained user experience and the best performance with maximum battery life.

For more details about CorePilot 4.0 technology please visit: www.mediatek.com/features/corepilot-evolution
For information on the MediaTek Helio family, please visit: https://www.mediatek.com/products/smartphones/mediatek-helio-x30

About MediaTek
MediaTek Incorporated (TWSE: 2454) is a global fabless semiconductor company that enables 1.5 billion connected devices a year. We are a market leader in developing innovative systems-on-chip (SoC) for mobile device, home entertainment, connectivity and IoT products. Our dedication to innovation has positioned us as a driving market force in several key technology areas, including highly power-efficient mobile technologies and advanced multimedia solutions across a broad range of products such as smartphones, tablets, digital televisions, OTT boxes, wearables and automotive solutions. MediaTek empowers and inspires people to expand their horizons and more easily achieve their goals through smart technology. We call this idea Everyday Genius and it drives everything we do. Visit www.mediatek.com for more information.

MediaTek Press Office:
PR@mediatek.com

Kevin Keating, MediaTek
+1- 206-321-7295
10188 Telesis Ct #500, San Diego, CA 92121, USA
Joey Lee, MediaTek
+886 3-567-0766 # 31602
No. 1, Dusing 1st Rd., Hsinchu Science Park, Hsinchu City 30078, Taiwan

 

Source: MediaTek Inc.

Related stocks: OTC-PINK:MDTKF Taiwan:2454

Written by asiafreshnews

March 1, 2017 at 10:40 am

Posted in Uncategorized